Company News for November 10, 2022

  • Shares of Akamai Technologies Inc. AKAM jumped 6.2% after reporting adjusted earnings per share of $1.26 in the third quarter of 2022, beating Zacks’ consensus estimate of $1.23.
  • Shares of Axon Enterprise Inc. AXON soared 14.6% after posting adjusted earnings per share of $0.60 in the third quarter of 2022, beating the Zacks consensus estimate of $0.46.
  • GMED shares of Globus Medical Inc. fell 4.2% after the company reported third quarter 2022 adjusted earnings per share of $0.50, missing the Zacks consensus estimate of $0.52.
  • SRC shares of Spirit Realty Capital Inc. gained 2.1% after the company reported adjusted earnings per share of $0.90 in the third quarter of 2022, beating the Zacks consensus estimate of $0.89.

Zacks names ‘only one best choice for doubling up’

From thousands of stocks, 5 Zacks experts have each picked their favorite to skyrocket by +100% or more in the coming months. Of these 5, Research Director Sheraz Mian selects one to have the most explosive advantage of all.

It’s a little-known chemical company that’s up 65% year-on-year, but still very cheap. With relentless demand, rising earnings estimates for 2022 and $1.5 billion for stock buybacks, retail investors could step in at any time.

This company could rival or surpass other recent Zacks stocks which are expected to double like Boston Beer Company which jumped +143.0% in just over 9 months and NVIDIA which jumped +175.9% in one year .

Free: See our best stock and our 4 finalists >>

Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report

Akamai Technologies, Inc. (AKAM): Free Inventory Analysis Report

Globus Medical, Inc. (GMED): Free Inventory Analysis Report

Spirit Realty Capital, Inc. (SRC): Free Stock Analysis Report

Axon Enterprise, Inc (AXON): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Karen J. Nelson